2. Lindsay R, Hart DM, Clark DM: The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63(6): 759-763

3. Christiansen C, Christensen MS, Transbol I: Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1(8218): 459-461

4. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al: Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979; 53: 277-281

5. Lindsay R: Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; 2(8205): 1151-1154

6. Kreiger N, Kelsey JL, Holford TR, et al: An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol 1982; 116(1): 141-148

7. Johnson RE, Specht EE: The risk of hip fracture in postmenopausal females with or without estrogen drug exposure. Am J Public Health 1981; 71(2): 138-144

8. Paganini-Hill A, Ross RK, Gerkins VR, et al: Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981; 95: 28-31

9. Weiss NS, Ure CL, Ballard JH, et al: Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195-1198

10. Hutchinson TA, Polansky SM, Feinstein AR: Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet 1979; 2(8145): 705-709

11. Naessen T, Persson I, Adami HO, et al: Hormone replacement therapy and the risk for first hip fracture. A prospective population-based cohort study. Am Intern Med 1990; 113: 95-103

12. Kiel DP, Felson DT, Anderson JJ, et al: Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987; 317: 1169-1174

13. Ettinger B, Genant HK, Cann CE: Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319-324

14. Grady D, Rubin SM, Petitti DB, et al: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117(12): 1016-1037

15. Gambrell RD Jr, Massey FM, Castaneda TA, et al: Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980; 55(6): 732-738

16. Steinberg KK, Thacker SB, Smith SJ, et al: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265(15): 1985-1990

17. Armstrong BK: Oestrogen therapy after the menopause-boon or bane? Med J Australia 1988; 148: 213-214

18. Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67-72

19. Hunt K, Vessey M, McPherson K, et al: Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620-635

20. Bergvist L, Adami HO, Persson I: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293-297

21. Mills PK, Beeson WL, Phillips RL, et al: Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer l989; 64: 591-597

22. Colditz GA, Stampfer MJ, Willett WC, et al: Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 1992; 3: 433-439

23. Bergkvist L, Adami H-O, Persson I, et al: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 130: 221-228

24. Miller AB: Risk/benefit considerations of antiestrogen / estrogen therapy in healthy postmenopausal women. Prev Med 1991; 20: 79-85

25. Persson I, Yuen J, Bergkvist L, et al: Combined oestrogen-progestogen replacement and breast cancer risk. [letter] Lancet 1992; 340(8826): 1044

26. Nachtigall MJ, Smilen SW, Nachtigall RD, et al: Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992; 80: 827-830

27. Bush TL, Barrett-Connor E, Cowan LD, et al: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75(6): 1102

28. Criqui M, Suarez L, Barrett-Connor E, et al: Postmenopausal estrogen use and mortality. Results from a prospective study in a defined homogenous community. Am J Epidemiol 1988; 128(3): 606-614

29. Wilson PW, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham study. N Engl J Med 1985; 313: 1038-1043

30. Stampfer MJ, Colditz GA, Willett WC, et al: Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991; 325: 756-762

31. Henderson BE, Paganini-Hill A, Ross RK: Decreased Mortality in Users of Estrogen Replacement Therapy. Arch Intern Med 1991; 151: 75-78

32. Wolf PH, Madans JH, Finucane FF, et al: Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991; 164: 489-494

33. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63

34. Barrett-Connor E: Estrogen and estrogen-progestogen replacement: Therapy and cardiovascular diseases. Am J Med 1993; 95(Suppl 5A): 40S-43S

35. van Hemert AM, Vandenbroucke JP, Birkenhager JC, et al: Prediction of osteoporotic fractures in the general population by a fracture risk score. Am J Epidemiol 1990; 132(1): 123-135

36. Kleerekoper M, Peterson E, Nelson D, et al: Identification of women at risk for developing postmenopausal osteoporosis with vertebral fractures: role of history and single photon absorptiometry. Bone Miner 1989; 7: 171-186

37. Pouilles JM, Tremollieres F, Louvet JP, et al: Sensitivity of dual-photon absorptiometry in spinal osteoporosis. Calcif Tissue Int 1988; 43: 329-334

38. Ott SM, Kilcoyne RF, Chesnut CH: III. Ability of four different techniques of measuring bone mass to diagnose vertebral fractures in postmenopausal women. J Bone Miner Res 1987; 2(3): 201-210

39. Wasnich RD, Ross PD, Heilbrun LK, et al: Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 1985; 153: 745-751

40. Hui SL, Slemenda CW, Johnston CC Jr: Baseline measurement of bone mass predicts fracture in white women. Ann Int Med 1989; 111: 355-361

41. Gardsell P, Johnell O, Nilsson BE: Predicting fractures in women by using forearm bone densitometry. Calcif Tiss Int 1989; 44: 235-242

42. Wasnich RD, Ross PD, Davis JW, et al: A comparison of single and multi-site BMC measurements for assessment of spine fracture possibility. J Nucl Med 1989; 30: 1166-1171

43. Cummings SR, Black DM, Nevitt MC, et al: Appendicular bone denisty and age predict hip fracture in women. JAMA 1990; 263(5): 665-668

44. U.S. Preventive Services Task Force: Guide to Clinical Preventive Services: an assessment of the effectiveness of 169 interventions. Williams & Wilkins, Baltimore, Md, 1989: 239-243

45. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-650

46. Canadian Task Force on the Periodic Health Examination: The periodic health examination: 2. 1987 update. Can Med Assoc J 1988; 138: 618-626